Vtv therapeutics inc. (VTVT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Revenue

8

7

8

1,828

921

4,522

3,375

2,473

2,064

-

15

13

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

30

-

38

182

376

226

133

110

50

400

Operating expenses:
Research and development

4,204

4,406

3,663

4,228

2,822

2,800

2,698

8,594

8,943

10,068

8,989

9,623

10,960

11,099

10,636

12,077

11,141

8,132

6,574

5,146

7,385

4,037

Research and development – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

0

529

72

194

815

585

556

391

291

General and administrative

2,450

1,989

1,770

2,392

2,386

2,073

2,158

2,737

2,255

2,937

2,567

3,005

2,824

2,252

2,401

2,672

2,581

2,370

2,415

2,297

1,995

1,592

Total operating expenses

6,654

6,395

5,433

6,620

5,208

4,873

4,856

11,331

11,198

13,005

11,556

12,628

13,784

13,351

13,566

14,821

13,916

11,317

9,574

7,999

9,771

5,920

Operating loss

-6,646

-6,388

-5,425

-4,792

-4,287

-351

-1,481

-8,858

-9,134

-12,772

-11,541

-12,615

-13,754

-13,313

-13,528

-14,639

-13,540

-11,091

-9,441

-7,889

-9,721

-5,520

Other income

-

-

-

1

-

0

10

0

36

-

-

-

-

-24

2

1

-1

13

-1

-1,510

660

-25

Other (expense) income – related party

-363

-223

-146

275

921

-1,248

319

316

-25

-

-

-

-

-

-

-

-

0

-56

-168

-168

-122

Interest income

12

12

15

16

10

14

13

16

18

22

35

33

27

21

21

22

23

-

-

-

-

-

Interest expense

168

283

404

514

626

743

822

870

855

852

849

832

559

395

0

1

2

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

-45

-45

-33

Interest expense, net related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

328

800

539

170

Loss before income taxes and noncontrolling interest

-7,165

-6,882

-5,960

-5,014

-3,982

-2,328

-1,961

-9,396

-9,960

-13,792

-12,355

-13,414

-14,286

-13,711

-13,505

-14,617

-13,520

-11,060

-9,822

-10,412

-9,813

-5,870

Income tax provision

0

0

0

100

0

0

0

200

0

800

0

0

0

0

0

0

0

-

-

-

-

0

Net loss before noncontrolling interest

-7,165

-6,882

-5,960

-5,114

-3,982

-2,328

-1,961

-9,596

-9,960

-14,592

-12,355

-13,414

-14,286

-13,711

-13,505

-14,617

-13,520

-11,060

-9,822

-10,412

-9,813

-5,870

Less: net loss attributable to noncontrolling interest

-2,441

-2,483

-2,352

-2,232

-1,827

-1,237

-1,165

-6,524

-7,008

-10,281

-8,705

-9,451

-10,066

-9,661

-9,512

-10,160

-9,668

-

-5,719

-

-

-

Net loss attributable to vTv Therapeutics Inc.

-4,724

-4,399

-3,608

-2,882

-2,155

-1,091

-796

-3,072

-2,952

-4,311

-3,650

-3,963

-4,220

-4,050

-3,993

-4,457

-3,852

-3,170

-4,103

-10,412

-9,813

-5,870

Net loss attributable to vTv Therapeutics Inc. common shareholders

-4,724

-5,033

-4,115

-2,882

-5,883

-1,830

-796

-3,072

-2,952

-

-

-

-

-

-

-

-

-

-

-

-

-

Class A Common Stock [Member]
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted

-0.11

-0.10

-0.13

-0.10

-0.26

-0.02

-0.06

-0.31

-0.30

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted

43,462

38,141

32,126

28,037

22,862

17,741

12,305

10,049

9,699

-

-

-

-

-

-

-

-

-

-

-

-

-